Viking Therapeutics (VKTX): Scientific Due Diligence for Lead and Pipeline Products

Check out my collaboration post here with The M&A Hunter and AT Investment Research for our comprehensive investment research on Viking Therapeutics (VKTX).

Viking Therapeutics is setting itself up to be a top fast follower candidate for the obesity and NASH/MASH market.

Executive Summary

The Reality Check: As of yesterday, we have entered the next chapter of the obesity treatment market. Novo Nordisk’s approval of the Wegovy® Pill (oral semaglutide) establishes a commercial monopoly starting January 2026. Viking may not be the pioneer, but they are a potential challenger.

The Hook:

Viking's lead asset, VK2735, is chemically similar to Eli Lilly’s Zepbound, but with a proprietary oral formulation that appears to work faster than Novo's newly approved pill. While Novo has secured the first mover advantage, Viking is positioning itself as the high potency alternative - a pill that hits harder and faster, potentially achieving in 13 weeks what takes Novo months to deliver.

The Bull Case:

Data suggests VK2735 is best-in-class for speed (12-15% weight loss in 13 weeks vs. Novo's 16.6% in 64 weeks). With Novo locking up the oral market, every other pharma giant (Pfizer, Roche, Amgen) is now desperate for a plug-and-play competitor. Viking has set themselves up as an unencumbered asset that can compete on efficacy.

The Bear Case:

Being second (or third) to market is expensive. Novo will spend the next two years building brand loyalty and formulary moats. Furthermore, Viking’s brute force delivery method requires massive API quantities and causes high vomiting rates at higher doses (35% in Phase 2). If they have a tough time with tolerability in Phase 3, they will likely be a niche, second-line drug for patients who fail Novo’s therapy.

Bottom Line:

The science is high-conviction. The commercial timeline is now under immense pressure. This stock has shifted from a growth story to a strategic necessity for M&A.

Catalyst Calendar & Financial Runway

Viking is currently cash-rich but burning fuel fast as they enter the expensive Phase 3 arena.

Upcoming Catalysts:

• Late 2025: End of Phase 2 Meeting with FDA for Oral VK2735.

• Q1 2026: Enrollment completion for VANQUISH-2 (Phase 3 in T2D/Obesity).

• Q1 2026: IND filing for the Amylin Agonist (potential “Next-Gen” weight loss asset).

• Jan 2026 (External): Novo Nordisk launches Wegovy Pill. Early prescription data will set the bar for market uptake.

Financial Bridge:

• Cash Position: $714.6M in cash/equivalents as of Sept 30, 2025.

• Burn Rate: Burned ~$193M in operations over the last 9 months. At this rate (~$65M/quarter), they should have roughly 2.5 years of runway (into 2028).

The Verdict: They do not necessarily need to raise cash immediately. They should have enough runway to get through the pivotal Phase 3 data readouts, which should put them in a position of strength for negotiations. But, they could be enticed to an early buyout by a player who wants to catch up to Novo.

Clinical Data

With Novo’s approval data now public, we can do a direct (albeit cross-trial) comparison.

Efficacy (The Good):

• Injectable (SC): In Phase 2, they hit ~14.7% weight loss at 13 weeks.

  • Reality Check: This is spectacular. For context, approved Wegovy hits ~15% in 68 weeks. Viking hits it in 13. It is arguably best-in-class speed.

• Oral: The Phase 2 data showed up to 12.2% weight loss at 13 weeks (120mg dose).

  • Novo (Wegovy Pill): 16.6% weight loss over 64 weeks.

  • Analysis: Viking’s drug is working roughly 4x faster. If Viking’s efficacy continues to compound (as seen in their injectable data), their terminal weight loss could hit 20%+, potentially positioning them as the superior option for patients needing aggressive intervention.

Safety (The Liability):

• Novo: Cited a well-known safety profile comparable to injectable Wegovy.

• Viking: Phase 2 data showed 35% vomiting at the highest efficacy doses.

• The Problem: In a market with a safe, approved option (Novo), patients will have zero tolerance for a pill that makes them sick. Viking must prove in Phase 3 that titration can bring GI side effects down to Novo's levels.

Mechanism & Chemistry Summary for VK2735

• Mechanism: VK2735 is a dual agonist (GLP-1/GIP), theoretically offering "synergy" (more weight loss, better metabolic profile) compared to Novo's mono-agonist (GLP-1 only). We know the mechanism works because Eli Lilly’s Zepbound does the exact same thing and is printing money. The mechanism is de-risked.

• The Tablet Technology: Viking uses a proprietary formulation to sneak the peptide through the stomach.

• The Trade-Off: To match the efficacy of an injection, Viking overloads the pill with active ingredient (API).

  • Receipts: Viking’s deal with CordenPharma for “metric tons” of pretty much confirms this inefficiency.

  • The Risk: High API load correlates with local stomach irritation. This likely drives the 35% vomiting rate seen at high doses.

Pipeline

While VK2735 grabs the headlines, Viking isn’t a one-trick pony. Here is the technical breakdown of the rest of the stable – where the hidden value (or hidden risks) might be lurking.

VK2809: The NASH/MASH Contender:

• Mechanism: Thyroid Hormone Receptor-beta (TRβ) Agonist.

• The Pitch: It’s the same mechanism as Madrigal’s Rezdiffra (resmetirom), the first and only FDA-approved drug for MASH (fatty liver disease). By selectively activating TRβ in the liver, it burns liver fat without the cardiac side effects (heart palpitations) associated with older thyroid drugs.

• The Data:

  • Effect Size: In the Phase 2b VOYAGE trial, VK2809 achieved up to 55% liver fat reduction at Week 52.

  • Histology: 75% of patients achieved NASH resolution without worsening of fibrosis (vs. 29% placebo). This is competitive with Rezdiffra’s pivotal data.

• The Problem: Madrigal has a massive first-mover advantage. For Viking to compete, they need to show superiority or a better safety profile. They are currently “me-too” in a market that rewards “first-in-class.”

• Status: Phase 2b complete. Awaiting a pivotal Phase 3 decision (likely needs a partner to fund it).

VK0214: The Rare Disease Play:

• Mechanism: Another TRβ Agonist (similar to VK2809), but optimized for X-Linked Adrenoleukodystrophy (X-ALD).

• The Science: X-ALD is a genetic disorder where Very Long-Chain Fatty Acids (VLCFAs) build up and destroy nerve protective coatings (myelin). VK0214 stimulates the ABCD2 transporter gene, which helps flush these toxic fats out of the system.

• The Data: In a Phase 1b study (Oct 2024), it successfully lowered plasma VLCFAs and lipids after just 28 days.

• The Reality Check: This is a tiny orphan market compared to obesity. It’s scientifically elegant but financially negligible unless they can charge orphan drug prices. It may validate their TRβ platform but likely won’t move the needle on the stock price like obesity data does.

The Amylin Agonist (DACRA):

• Mechanism: Dual Amylin and Calcitonin Receptor Agonist (DACRA).

• The Hype: Amylin is the new hot commodity in obesity because it has been shown to cause weight loss without the nausea associated with GLP-1s. Novo Nordisk’s CagriSema (Amylin + GLP-1) is currently the gold standard for next-gen efficacy.

• The Status: Preclinical. IND filing expected Q1 2026.

• Why It Matters: This is Viking’s hedge. If GLP-1s become commoditized, Amylin is looking like the next frontier. Developing their own proprietary Amylin allows them to create a “CagriSema” competitor in-house (VK2735 + Amylin) without relying on licensing.

Pipeline Verdict: A Fast Follower Factory

Viking’s pipeline confirms their corporate DNA: they identify validated mechanisms (TRβ for MASH, GLP-1/GIP for Obesity, Amylin for Next-Gen Obesity) and execute highly competent chemistry to produce “best-in-class” contenders. They are not inventing new biology; they are optimizing known winners. This reduces scientific risk but increases commercial pressure to differentiate.

Biochemical Deep Dive:

To understand the moat, you must understand the molecules. Viking isn’t necessarily inventing new biochemistry/biology; they are optimizing known winners.

A. VK2735: The Dual Agonist Synergy

• The Mechanism: VK2735 activates two different receptors: GLP-1 (Glucagon-like peptide-1) and GIP (Glucose-dependent insulinotropic polypeptide).

  • GLP-1 is the brake pedal for appetite. It slows down stomach emptying and tells your brain you’re full.

  • GIP is the turbocharger. It enhances insulin secretion but also – crucially – improves fat metabolism (and may reduce the nausea associated with pure GLP-1s).

  • The Investment Implication: By hitting both, you get synergy – more weight loss than GLP-1 alone (like Wegovy) without necessarily doubling the side effects. This is the same biology that powers Lilly’s Zepbound, which is currently the efficacy king. Viking isn’t reinventing the wheel; they are optimizing the tire tread.

B. The Oral Challenge:

• The Problem: Peptides (like VK2735) are just chains of amino acids. If you swallow them, your stomach treats them like a steak dinner – it digests them before they can get to work.

• Viking’s Solution: They haven’t disclosed the exact formulation (trade secret), but the data suggests they may have solved the permeability problem. They appear to be sneaking the large peptide molecule through the stomach lining intact.

• The Biological Cost: To get enough drug across, you often need to overload the pill with API. However, local irritation in the stomach likely drives the ~35% vomiting rate at high doses. The biology works, but the physiology is rebelling at higher doses. That said, if Viking can nail the therapeutic window with an optimal dose, they become highly attractive.

C. VK2809: MASH

• The Mechanism: Thyroid hormone burns fat, but it also races your heart (tachycardia) and eats your bones. This is because thyroid receptors are everywhere (Heart = TRα, Liver = TRβ).

• The Innovation: VK2809 is a prodrug that is chemically modified to be inactive until it hits a specific enzyme (CYP3A4) found abundantly in the liver.

• The Result: It becomes active only where you want it (the liver) and stays inactive near the heart.

• The Reality Check: The data appears to back this up. In the VOYAGE trial, patients saw massive liver fat reduction (up to 55%) with no significant cardiac side effects. This liver selectivity is the scientific moat that separates it from generic thyroid hormone.

D. Amylin (DACRA): The Anti-Nausea Hope

• The Mechanism: Amylin is a hormone co-secreted with insulin. It signals satiety (fullness) through a different pathway than GLP-1s.

• The Angle: Amylin agonists historically cause weight loss without the severe gastrointestinal distress (nausea/vomiting) typical of GLP-1s.

• The Combo Play: Viking’s DACRA (Dual Amylin Calcitonin Receptor Agonist) is being designed to be stacked on top of VK2735. In animal models, this combination melts fat faster than either drug alone.

• The Investment Implication: If GLP-1s hit a tolerability ceiling (where patients quit because they feel sick), Amylin is currently a top candidate for the next logical step. Viking having this in-house means they would be able to formulate their own CagriSema competitor (Novo’s super drug) without paying royalties to anyone else.

Intellectual Property

The summary below is based on the Form 10-K filed February 26, 2025.

1. Core Strategy: The Ligand Master License

Viking’s intellectual property (IP) position appears partially dependent on a Master License Agreement with Ligand Pharmaceuticals. Viking does not appear to originally own the core composition-of-matter patents for its lead assets; instead, it looks like they hold an exclusive, worldwide, royalty-bearing license to develop and commercialize them.

• Scope: The license appears to cover the TRβ program (VK2809, VK0214), the SARM program (VK5211), and other earlier-stage assets (VK0612, DGAT-1, EPOR).

• Terms: Viking appears to owe Ligand tiered royalties (low-to-upper single digits) on future net sales and up to $1.54 billion in aggregate milestone payments.

• Risk: If Viking defaults on payment or diligence obligations, Ligand may have the right to terminate the license, which would effectively end Viking’s ability to develop these drug candidates.

2. Patent Portfolio Status (as of Dec 31, 2024)

Viking reports owning or co-owning 144 patent applications and 35 patents, in addition to the rights in-licensed from Ligand. Here is a summary of the IP position (as of Dec 31, 2024) reported in the 10-K.

A. Metabolic Programs (Obesity & MASH)

• GLP-1/GIP Agonists (VK2735):

  • Estate: 4 issued patents and 59 pending applications.

  • Term: Nominal patent terms seem to run from 2042 to 2044, offering a longer runway for commercialization if approved.

  • Ownership: The 10-K notes Viking owns one U.S. patent and additional foreign patents for this program, indicating they are building their own moat around the specific VK2735 molecule and formulation, separate from the Ligand-licensed assets.

• TRβ Agonists (VK2809 & VK0214):

  • Estate: 39 issued patents and 81 pending applications worldwide.

  • Term: Expiration dates range from 2025 to 2043.

  • Structure: For VK2809, Viking appears to in-license three U.S. patents and owns/co-owns two additional U.S. patents.

B. Other Programs

• VK5211 (SARM): 21 issued patents and 13 pending applications with terms expiring between 2025 and 2040.

• Dual Amylin/Calcitonin (DACRA): Viking appears to own one PCT application and additional U.S./foreign applications for this internal program.

3. Litigation & Enforcement

Viking is enforcing its IP rights already, specifically regarding trade secrets rather than patents.

• Ascletis Litigation: Viking filed suit against Ascletis Bioscience (and affiliates) for misappropriation of trade secrets related to VK2735. In October 2024, an International Trade Commission (ITC) judge ruled in Viking’s favor, finding that Ascletis misappropriated trade secrets. This ruling was affirmed by the full ITC Commission in May 2025.

The Verdict

Scientific Conviction: High.

The drugs are working so far. The biological mechanisms are sound and validated by competitors.

Commercial Viability: Medium.

Novo has first mover advantage. Further, the vomit factor (35%) and the manufacturing intensity (metric tons of peptide) compress chance of success as well as the profit margins and adoption curve, if successful.

The M&A Appeal: Extreme.

This is the perfect bolt-on for a major pharma company (Merck, Roche) that missed the GLP-1 wave. Buying Viking instantly gives them a Phase 3 injectable and a Phase 3-ready oral pill. The deal logic is undeniable.

Trader Profile: Value Holders and Binary Event Gamblers

Final Verdict: Buy / Hold or Buy on Dips, Sell on Peaks

The valuation reflects a lot of success already. The upside depends on either (A) fixing the vomiting issue in Phase 3 or (B) a buyout offer. Seems like the play is to accumulate if the stock dips on macro news, but be wary of the safety profile limiting the ultimate market size.

THE BUY CASE

Thesis: Pfizer, Roche, and AstraZeneca are now staring at a Novo monopoly in the oral market. They cannot wait 5 years to develop their own asset. Viking is setting up to be an attractive asset that can commercially rival Novo’s efficacy. The “Ligand Tax” is a rounding error for a desperate mega-cap.

Action: Accumulate on dips.

THE HOLD CASE

Thesis: Novo has set a safety benchmark Viking hasn't met yet. Until Phase 3 data proves that slow titration eliminates the 35% vomiting rate, Viking has a “better” drug that nobody will take.

Action: Hold current position. Wait for Phase 3 safety run-in data.

THE SELL CASE

Thesis: By the time Viking launches (2027/28), Novo will have locked up insurance formularies. Launching a second-to-market drug with higher manufacturing costs (metric tons of API) into a genericized market is a recipe for capital destruction.

Trigger: Sell if they announce a “Go It Alone” commercial strategy instead of a partnership/sale.

Disclaimer: This is not financial advice. I am a chemist and an analyst, not your wealth manager. Biopharma stocks are volatile and can go to zero. Do your own due diligence.

This report is for informational and educational purposes only and does not constitute investment advice, a recommendation to buy/sell securities, or an offer to sell. Investing in biotechnology involves extreme risk, including the loss of principal.

This analysis reviews clinical data for investment due diligence. It is not medical guidance. Do not change your medical treatment based on a newsletter.

At the time of writing, the author holds a small position in Viking Therapeutics (VKTX) consisting of common stock.

Past scientific validation (like Phase 2 data) does not guarantee future Phase 3 success. Safety signals often emerge only in larger populations.